Hypertension
Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.
Where it strikes
Glomerular & peritubular capillaries
Filtration barrier (podocytes + endothelium)
Agents’ overall severity
Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.
Agents’ overall reversibility
Agents’ onset window
How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.
Real-world reporting for this lesion
FAERS across all lesions →How disproportionately hypertension is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.
Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.
Documented in a profile with no reporting signal. 5 of 7 sit on a reportable term with enough reports, so FAERS could have flagged the lesion and did not; the rest are expected silences.
A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.
The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.
- LenvatinibVEGFR TKI13.61 (13.27–13.96) · n=7,510 Reporting signal.
- NiraparibPARP inhibitor10.09 (9.74–10.46) · n=3,641 Reporting signal.
- TivozanibVEGFR TKI9.89 (8.61–11.36) · n=235 Reporting signal.
- OctreotideSomatostatin analog · FAERS only9.38 (9.09–9.67) · n=4,759 Reporting signal.
- NaxitamabAnti-GD2 antibody8.87 (6.25–12.57) · n=37 Reporting signal.
- VandetanibVEGFR/EGFR/RET TKI7.18 (6.04–8.54) · n=144 Reporting signal.
- FruquintinibVEGFR TKI7.00 (6.36–7.71) · n=475 Reporting signal.
- AxitinibVEGFR TKI6.63 (6.34–6.93) · n=2,235 Reporting signal.
- CabozantinibVEGFR/MET TKI6.39 (6.21–6.57) · n=5,301 Reporting signal.
- PralsetinibRET inhibitor5.73 (4.92–6.67) · n=184 Reporting signal.
- RegorafenibVEGFR TKI5.65 (5.32–6.01) · n=1,155 Reporting signal.
- SorafenibVEGFR TKI4.75 (4.53–4.99) · n=1,757 Reporting signal.
- CopanlisibPan-PI3K inhibitor4.58 (3.16–6.64) · n=30 Reporting signal.
- SunitinibVEGFR TKI4.55 (4.38–4.72) · n=3,180 Reporting signal.
- SelpercatinibRET inhibitor4.44 (3.63–5.44) · n=101 Reporting signal.
- PazopanibVEGFR TKI4.34 (4.16–4.54) · n=2,106 Reporting signal.
- PonatinibBCR-ABL TKI3.81 (3.53–4.11) · n=714 Reporting signal.
- PexidartinibCSF1R inhibitor · FAERS only3.74 (2.80–5.00) · n=49 Reporting signal.
- RipretinibKIT switch-control inhibitor3.45 (3.09–3.86) · n=332 Reporting signal.
- BevacizumabAnti-VEGF antibody3.42 (3.34–3.50) · n=8,088 Reporting signal.
- RituximabAnti-CD20 antibody · FAERS only3.29 (3.23–3.35) · n=12,891 Reporting signal.
- VimseltinibCSF1R tyrosine kinase inhibitor · FAERS only3.26 (2.30–4.64) · n=33 Reporting signal.
- RaltitrexedAntifolate (TS inhibitor) · FAERS only3.03 (2.15–4.28) · n=34 Reporting signal.
- BrigatinibALK TKI2.86 (2.48–3.31) · n=194 Reporting signal.
- LanreotideSomatostatin analog · FAERS only2.74 (2.48–3.03) · n=405 Reporting signal.
- PenpulimabPD-1 immune checkpoint inhibitor · FAERS only2.74 (1.12–6.75) · n=5 Reporting signal, fragile (few reports).
- PembrolizumabPD-1 checkpoint inhibitor · FAERS only2.59 (2.51–2.66) · n=4,694 Reporting signal.
- AsciminibBCR-ABL STAMP inhibitor2.43 (2.06–2.88) · n=144 Reporting signal.
- EverolimusmTOR inhibitor · FAERS only2.33 (2.23–2.43) · n=2,159 Reporting signal.
- Methotrexate (high-dose)Antifolate · FAERS only2.14 (2.11–2.17) · n=19,305 Reporting signal.
- RamucirumabAnti-VEGFR2 antibody2.02 (1.78–2.30) · n=241 Reporting signal.
- CarfilzomibProteasome inhibitor1.84 (1.73–1.96) · n=986 Reporting signal.
- NintedanibVEGFR/FGFR/PDGFR TKI1.78 (1.67–1.89) · n=1,102 Reporting signal.
- DinutuximabAnti-GD2 antibody1.78 (1.23–2.58) · n=29 Reporting signal.
- AbirateroneCYP17 inhibitor1.58 (1.49–1.67) · n=1,233 Reporting signal.
- IbrutinibBTK inhibitor1.45 (1.39–1.51) · n=2,237 Reporting signal.
- EnzalutamideAndrogen-receptor inhibitor1.41 (1.34–1.49) · n=1,585 Reporting signal.
- Trastuzumab emtansine (T-DM1)Antibody-drug conjugate (HER2/DM1)1.35 (1.18–1.54) · n=218 Reporting signal.
- Ziv-afliberceptVEGF trap1.24 (1.15–1.33) · n=773 Reporting signal.
- AcalabrutinibBTK inhibitor0.93 (0.82–1.06) · n=228 No reporting signal.
- GemcitabineNucleoside analog0.78 (0.73–0.84) · n=816 No reporting signal.
- LeuprolideGnRH agonist0.73 (0.69–0.78) · n=1,131 No reporting signal.
- TrametinibMEK inhibitor0.62 (0.56–0.70) · n=294 No reporting signal.
reporting odds ratio (log) — no signal left of the dashed line at 1.0
No ratio — no HTN reports, or too few (count in brackets): Relacorilant
No ratio — under 50 FAERS reports in total: Ivonescimab, Olverembatinib
No FAERS reports under the agent's name: Iobenguane I-131
All 37 agents documented with HTN in the atlas are shown whether or not FAERS flags them, plus the 34 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). Class composites (VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib)) are not asked of FAERS; their member agents are ranked individually. 63 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR; * a signal carried by terms consistent with the lesion, not naming it. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.
Management approach
Full framework →An expected effect (on-target with VEGF-pathway agents) — treat the blood pressure and usually continue the drug.
Drug-level levers
- Continue the agent if blood pressure is controlled (with VEGF-pathway agents, hypertension correlates with on-target activity).
- Hold for severe/refractory hypertension or a hypertensive emergency; resume once controlled.
- Dose-reduce for grade 3 hypertension not controlled on therapy.
Pharmacologic toolkit
- Antihypertensives — An ACE inhibitor/ARB (also helps any proteinuria) and/or a dihydropyridine calcium-channel blocker are common first choices; avoid non-dihydropyridine CCBs with CYP3A4-metabolized TKIs.
When to biopsy
Not indicated for isolated hypertension.
Monitoring
- · Home and clinic blood pressure, especially in the first cycles
- · Urine protein
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
What the guidelines say
All guidelines →Society and consensus recommendations that speak to hypertension.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
Cited incidence across agents
Where the literature gives a representative hypertension figure, the agents ranked highest first. Hover a dot for its cited note.
Offending agents
Signature offenders
24Agents for which hypertension is the defining renal lesion.
Also associated
14Agents that cause hypertension as a secondary pattern alongside a different signature lesion.